Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Low Carbohydrate, High Protein Diet Slows Tumor Growth

By HospiMedica International staff writers
Posted on 19 Jul 2011
A new study suggests that a low carbohydrate (CHO) diet not only restricts weight gain but also slows cancer development and progression.

Researchers at the British Columbia Cancer Research Center (BCCRC; Vancouver, Canada) compared the effects of low CHO diets to a Western diet on the growth rate of tumors in a mouse model. More...
To avoid caloric restriction–induced effects, the low CHO diets were designed to be of an isocaloric value with the Western diet by increasing protein rather than fat levels, due to the reported tumor-promoting effects of high fat and the immune-stimulating effects of high protein.

The researchers found that both murine and human carcinomas grew slower in mice on diets containing low amylose CHO and high protein, compared with a Western diet characterized by relatively high CHO and low protein. There was no weight difference between the tumor-bearing mice on the low CHO or Western diets. Additionally, the low CHO-fed mice exhibited lower blood glucose, insulin, and lactate levels. Strikingly, in a genetically engineered mouse model of mammary cancer, tumor penetration in mice on a Western diet was nearly 50% by the age of one year, whereas no tumors were detected in mice on the low CHO diet; this difference was associated with weight gains in mice on the Western diet not observed in mice on the low CHO diet. Moreover, whereas only one mouse on the Western diet achieved a normal life span, due to cancer-associated deaths, more than 50% of the mice on the low CHO diet reached or exceeded the normal life span. The study was published in the July 1, 2011, issue of Cancer Research.

“A high amylose containing low CHO, high protein, diet reduces blood glucose, insulin, and glycolysis, slows tumor growth, reduces tumor incidence, and works additively with existing therapies without weight loss or kidney failure,” concluded lead author Victor Ho, PhD, and colleagues. “Such a diet, therefore, has the potential of being both a novel cancer prophylactic and treatment, warranting further investigation of its applicability in the clinic, especially in combination with existing therapies.”

Amylose is a polysaccharide made up of D-glucose units. It is one of the two components of starch, making up approximately 20%-30% of the structure; the other component is amylopectin, which makes up 70%-80% of the structure. Because of its tightly packed structure, amylose is more resistant to digestion than other starch molecules and is therefore an important form of resistant starch, which has been found to be an effective prebiotic. High-amylose varieties of long-grain rice have a much lower glycemic load, which could be beneficial for diabetics.

Related Links:
British Columbia Cancer Research Center




Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.